Sponsors are shedding light on our expertise with infectious diseases

Algorithme Pharma
e-Bulletin   |  October 2015  
Sponsors are shedding light on our expertise with infectiours diseases!

"In less than three months, Algorithme Pharma completed the first part of our study in sequential dose escalation of 48 Healthy Volunteers and 15 Genotype1 hepatitis C virus (HCV) infected subjects. In a highly competitive environment, they also successfully participated in the multiple dosing of several genotype HCV infected subjects, and delivered six subjects within two months."

— Marie-Françoise TEMAM

Associate Director, Clinical Operations, Idenix, a wholly-owned subsidiary of Merck & Company
Partnered with Algorithme Pharma on a Proof of Concept Phase I/IIa Hepatic C Virus Infection Study.


Read the full testimonial and learn more about our therapeutic expertise.


450 973-6077  |  888 267-7449  |  contact@algopharm.com
©2015 All Rights Reserved, Algorithme Pharma inc.